Value based pricing for NHS drugs: an opportunity not to be missed?
Where this comes from
- Record sourced from PubMed, PMID 18244997.
- Also identified by DOI 10.1136/bmj.39434.500185.25 and PMC identifier 2223028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The policy debate about price, value, and innovation in pharmaceuticals is at a critical stage for the NHS. <b>Claxton and colleagues</b> describe the key principles of value based pricing and consider some of the concerns about such a scheme
Medical subject headings
- Drug Costs
- Pharmaceutical Preparations
- State Medicine